Candriam S.C.A. significantly reduced its holdings in Labcorp Holdings Inc. during the third quarter, cutting its stake by 39.3%. The investment firm now holds 46,666 shares of Labcorp, valued at approximately $13.4 million. Despite this reduction by an institutional investor, financial analysts maintain a "Moderate Buy" consensus for Labcorp. The stock holds an average price target of $300.75, bolstered by recent upgrades from firms like JPMorgan and Mizuho. Furthermore, Labcorp recently declared a quarterly dividend of $0.72 per share, indicating a 1.0% yield. This combination of institutional selling and positive analyst outlook, alongside a dividend declaration, presents a mixed picture for the diagnostic services provider.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis